A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy

Clinical trial NCT07774520 · RECRUITING

Trial details

NCT number: NCT07774520
Sponsor: Samsung Medical Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer(NSCLC)EGFR Mutant

Start date: 2026-05-26
Primary completion: 2029-06-01
Enrollment: 1173

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.